论文部分内容阅读
目的观察痰热清治疗手足口重症的临床疗效。方法将37例手足口重症患儿随机分为治疗组19例与对照组18例。对照组予甘露醇降颅压,静脉点滴利巴韦林10～15mg/kg.d,控制液体入量,酌情应用丙种球蛋白、糖皮质激素,同时给予氧疗和呼吸支持,必要时应用血管活性药物;治疗组在对照组治疗的基础上加用痰热清0.5ml/kg.d静脉点滴。对比分析两组的临床疗效。结果两组在体温消退时间、主要症状消失时间及住院时间方面比较差异均有统计学意义(P<0.01)。结论痰热清辅助治疗手足口重症疗效好、无明显不良反应。
Objective To observe the clinical efficacy of Tanreqing in treating hand-foot-mouth severe diseases. Methods A total of 37 children with HFMD were randomly divided into treatment group (n = 19) and control group (n = 18). Control group to mannitol intracranial pressure, intravenous ribavirin 10 ~ 15mg / kg.d, control of fluid intake, as appropriate, the application of gamma globulin, glucocorticoid, given oxygen therapy and respiratory support, if necessary, the use of blood vessels Active drugs; treatment group in the control group based on the treatment plus Tanreqing 0.5ml / kg.d intravenous drip. Comparative analysis of two groups of clinical efficacy. Results There were significant differences between the two groups in the regression of body temperature, the disappearance of the main symptoms and the length of hospital stay (P <0.01). Conclusion Tanreqing adjuvant treatment of hand, foot and mouth severe effect, no obvious adverse reactions.